

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application.

Cancel Claims 1, 8, 10, 11, 14, 17, 22, 23, and 25-41.

Listing of Claims:


1. (cancelled)

2. (amended) The compound of Claim 1 ~~42~~ of the formula Ia:




or a pharmaceutically acceptable salt thereof.

3. (original) The compound of Claim 2 of the formula Ib:




or a pharmaceutically acceptable salt thereof.

4. (original) The compound of Claim 3 of the formula Ic:




or a pharmaceutically acceptable salt thereof.

5. (original) The compound of Claim 3 of the formula Id




or a pharmaceutically acceptable salt thereof.

6. (original) The compound of Claim 2 of the formula Ie:



or a pharmaceutically acceptable salt thereof.

7. (original) The compound of Claim 6 of the formula If:



(If)

or a pharmaceutically acceptable salt thereof.

8. (cancelled)

9. (amended) The compound of Claim 8 ~~42~~ wherein Ar is selected from the group consisting of:

- (1) phenyl,
- (2) 2-fluorophenyl,
- (3) 3,4-difluorophenyl,
- (4) 2,5-difluorophenyl,
- (5) 2,4,5-trifluorophenyl, and
- (6) 2-fluoro-4-(trifluoromethyl)phenyl.

10-11. (cancelled)

12. (amended) The compound of Claim ~~11~~ ~~42~~ wherein R¹ is selected from the group consisting of:

- (1) hydrogen,
- (2) methyl,
- (3) ethyl,
- (4) CF₃, and
- (5) CH₂CF₃.

13. (original) The compound of Claim 12 wherein R¹ is hydrogen or CF₃.

14. (cancelled)

15. (amended) The compound of Claim ~~14~~ 42 wherein R^2 is selected from the group consisting of:

- (1) hydrogen,
- (2) methyl,
- (3) ethyl,
- (4) CF_3 ,
- (5) CH_2CF_3 ,
- (6) CF_2CF_3 ,
- (7) phenyl,
- (8) (4-methoxy)phenyl,
- (9) (4-trifluoromethoxy)phenyl,
- (10) 4-fluorophenyl, and
- (11) 3,4-difluorophenyl.

16. (amended) The compound of Claim 15 wherein R^2 is CF_3 or CF_2CF_3 .

17. (cancelled)




18. (amended) The compound of Claim ~~17~~ 42 wherein R^5 and R^6 are independently selected from the group consisting of:

- (1) hydrogen,
- (2) CH_3 ,
- (3) CH_2CH_3 ,
- (4) $CH(CH_3)_2$,
- (5) $COOCH_3$,
- (6) CH_2 -phenyl,
- (7) 3-fluorophenyl, and
- (8) 2-(trifluoromethyl)phenyl,

with the proviso that one of R^5 and R^6 is other than hydrogen.

19. (original) The compound of Claim 18 wherein R⁵ and R⁶ are independently hydrogen or CH₃, with the proviso that one of R⁵ and R⁶ is other than hydrogen.





20. (original) A compound which is selected from the group consisting of:



Serial No.: 10/508,898

Case No.: 21070YP





Page No.: 7



Serial No.: 10/508,898

Case No.: 21070YP





Page No.: 8



Serial No.: 10/508,898

Case No.: 21070YP





Page No.: 9






Serial No.: 10/508,898

Case No.: 21070YP

Page No.: 10





or a pharmaceutically acceptable salt thereof.

21. (amended) A pharmaceutical composition which comprises an inert carrier and a compound of Claim 42.


22-23. (cancelled)

24. (amended) A method for treating, controlling, ameliorating or reducing the risk of non-insulin dependent (Type 2) diabetes mellitus in a mammalian patient in need of

such treatment which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1 42.

25-41. (cancelled)

42. (new) 1. A compound of the formula I:



I

or a pharmaceutically acceptable salt thereof; wherein

Ar is phenyl which is unsubstituted or substituted with 1-5 substituents which are independently selected from the group consisting of:

- (1) fluoro,
- (2) chloro, and
- (3) CF₃;

X is selected from the group consisting of:

- (1) N and
- (2) CR²;

R¹ is selected from the group consisting of:

- (1) hydrogen and
- (2) C₁₋₆ alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 fluorines;

R² is selected from:

- (1) hydrogen and

- (2) C₁₋₆alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 fluorines; and

R⁵ and R⁶ are independently selected from the group consisting of:

- (1) hydrogen,
- (2) C₁₋₁₀ alkyl, which is linear or branched and which is unsubstituted or substituted with one or more substituents selected from:
 - (a) halogen,
 - (b) phenyl, wherein the phenyl is optionally substituted with 1-5 substituents independently selected from halogen, OH, C₁₋₆ alkyl, and C₁₋₆ alkoxy, wherein the C₁₋₆ alkyl and C₁₋₆ alkoxy are linear or branched and optionally substituted with 1-5 halogens, and
- (3) phenyl which is unsubstituted or substituted with 1-3 substituents independently selected from C₁₋₆alkyl, OC₁₋₆alkyl, and halogen, wherein the C₁₋₆alkyl and OC₁₋₆alkyl are linear or branched and optionally substituted with 1-5 halogens, and
- (4) CO₂C₁₋₆ alkyl;

with the proviso that one of R⁵ and R⁶ is other than hydrogen.